SOURCE: DNAPrint Genomics, Inc.

November 15, 2007 07:30 ET

DNAPrint® Genomics and Beckman Coulter Sign Sales and Marketing Agreement for DNAWitness™ and AncestryByDNA™

DNAWitness™ Kits Along With SNPStream® Genotyping Systems Offered to the Forensics Community

SARASOTA, FL--(Marketwire - November 15, 2007) - DNAPrint® Genomics, Inc. (OTCBB: DNAG) today announced that it has entered into a sales and marketing agreement with Beckman Coulter, Inc., of Fullerton, CA, around DNAPrint's proprietary AncestryByDNA™ and DNAWitness™ technologies, utilizing Beckman Coulter's SNPStream® Genotyping Systems.

"As a primary focus, DNAPrint® can provide detectives with the new DNAWitness™ descriptor kit that their own crime labs can run," said Richard Gabriel, CEO and President of DNAPrint® Genomics, Inc.

DNAPrint's sophisticated Ancestry DNA technology can determine genetic ancestry and provide law enforcement a "fuzzy photograph" of an individual from a DNA sample.

Forensic investigators can use the technology to acquire a description of a suspect or to help them identify unknown victims. "Crime labs or law enforcement agencies can purchase the SNPStream® from either company. It is similar to the pharmaceutical product called 'PharmaID™', which is a high performance technology of validated DNA testing and identification used to predict drug reactions in certain population groups," said Mr. Gabriel. "Forensics, however, is our primary focus."

Statistics from US Department of Justice indicate that major cities can have 5,000 to 10,000 unsolved murders, dating as far back as 1960. Mr. Gabriel noted, "In 1960, this technology was science fiction. Today we are using it to arrest dangerous criminals -- repeat murderers, rapists and child molesters -- and to free innocent people who were incarcerated by a wrongful conviction.

"Because of the unconscionable backlog of nearly a half million untested rape kits and entries in the national CODIS system, criminals are free to continue their terror. Victims' rights remain frozen, due to lack of funding to acquire the now-available technology to solve a majority of these crimes. Today, DNAPrint® can help forensic laboratories across the globe to reach beyond CODIS and utilize these powerful technologies," Mr. Gabriel concluded.

"DNAWitness™ has been used in nearly 200 cases across the U.S., Great Britain and Canada. Many of these cases would go unsolved because there are no credible witnesses to testify on the victim's behalf or there are no reliable descriptions of the victim's remains," said Dr. Tony Frudakis, Founder and Chief Scientific Officer of DNAPrint® Genomics, Inc. "Now DNAWitness™ Kits and SNPStream® Genotyping Systems are easily available to every forensic laboratory across the globe. We are very excited about this new relationship to broaden the use of DNAWitness™ technologies in the forensic and detective communities."

"Using DNAWitness™, investigators have changed the primary direction of investigations, saving time and money, and lessening the risk of the suspect committing additional crimes," said Dr. Mathew Thomas, a Senior Scientist and Laboratory Manager of DNAPrint® Genomics, Inc. "Our technology can significantly narrow the field of suspects, leaving investigators to more thoroughly investigate the substantial credible leads."

About DNAPrint® Genomics, Inc.

DNAPrint® Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint® is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWitness™, RETINOME™, AncestryByDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint® Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    941-366-3400
    -or-
    Ron Stabiner
    The Wall Street Group, Inc.
    212-888-4848